Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Hemophilia B, Moderately Severe or Severe: early-phase trial registry

1 of 1 indexed Hemophilia B, Moderately Severe or Severe trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Hemophilia B, Moderately Severe or Severe: 1 US clinical trial tracked, 1 recruiting.

Hemophilia B, Moderately Severe or Severe is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Be Biopharma, running 1 of these trials.

Enrollment posture brief

Registry condition hemophilia-b-moderately-severe-or-severe

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Hemophilia B, Moderately (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Hemophilia B, Moderately Severe or Severe

Hemophilia B, Moderately Severe or Severe lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hemophilia B, Moderately Severe or Severe on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hemophilia B, Moderately Severe or Severe is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Be Biopharma 1 trials

Named interventions

Most-linked intervention names on Hemophilia B, Moderately Severe or Severe records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

BE-101 Drug
1 trials

US sites by state

Facility locations filed on Hemophilia B, Moderately Severe or Severe trials. A trial with sites in several states counts in each.

Washington 1 trials
Minnesota 1 trials
Michigan 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hemophilia B, Moderately Severe or Severe page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Hemophilia B, Moderately Severe or Severe trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Be Biopharma sponsors the most Hemophilia B, Moderately Severe or Severe trials on record, review their full trial history before evaluating a specific study. See Be Biopharma's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hemophilia B, Moderately Severe or Severe condition card totals 1 registered trials; most-linked intervention BE-101; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.